https://kriyatherapeutics.com/news/kriya-announces-publication-of-preclinical-data-showing-aav-fgf21-gene-therapy-extended-health-span-and-lifespan-in-aged-mice2026-08-17T10:56:34-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-selected-for-fda-precheck-pilot-program2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-announces-presentations-at-asgct-2026-highlighting-advances-across-gene-therapy-platform2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-appoints-sachiyo-minegishi-as-chief-financial-officer2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-appoints-greg-di-russo-md-as-chief-medical-officer2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya_announces_320_million_series_d_financing_to_advance_pipeline_of_gene_therapies_for_chronic_diseases_of_high_unmet_need2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-presents-data-at-the-2025-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-announces-thirteen-presentations-at-the-american-society-of-gene-cell-therapy-asgct-annual-meeting-20252026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-announces-publication-of-preclinical-data-for-its-investigational-aav-fgf21-gene-therapy-demonstrating-durable-reversal-of-liver-fibrosis2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-highlights-positive-preclinical-data-for-kriya-586-a-gene-therapy-product-candidate-for-thyroid-eye-disease-ted-at-esoprs-annual-meeting2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-appoints-scientific-co-founder-j-fraser-wright-ph-d-as-chief-gene-therapy-officer2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-appoints-katherine-eade-as-chief-legal-officer2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-announces-three-presentations-at-the-2024-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-announces-six-presentations-at-the-american-society-of-gene-cell-therapy-asgct-annual-meeting-20242026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-provides-update-on-pipeline-progress-ahead-of-company-presentation-at-42nd-annual-j-p-morgan-healthcare-conference2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-announces-gene-therapy-program-for-thyroid-eye-disease2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-to-present-at-the-j-p-morgan-42nd-annual-healthcare-conference2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-announces-exclusive-license-and-collaboration-agreement-with-everads-to-advance-gene-therapies-for-prevalent-diseases-in-ophthalmology-including-geographic-atrophy2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-acquires-tramontane-therapeutics-and-launches-gene-therapy-program-for-nonalcoholic-steatohepatitis-nash-and-other-prevalent-diseases2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-announces-150-million-addition-to-its-series-c-bringing-total-round-to-over-430-million-to-further-its-mission-of-delivering-gene-therapies-for-prevalent-diseases2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-to-present-10-abstracts-at-the-2023-american-society-of-gene-and-cell-therapy-annual-meeting2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-acquires-redpin-therapeutics-adding-neurology-pipeline-to-gene-therapy-portfolio2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-appoints-curt-herberts-as-president-and-chief-operating-officer2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-announces-270-million-series-c-financing-to-advance-fully-integrated-gene-therapy-engine2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-licenses-next-generation-complement-targeted-gene-therapies-for-the-treatment-of-geographic-atrophy-and-other-ocular-diseases2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-therapeutics-completes-renovation-of-its-facility-for-scalable-gene-therapy-manufacturing2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-therapeutics-completes-100-million-series-b-financing-to-advance-its-fully-integrated-platform-for-designing-developing-and-manufacturing-transformative-gene-therapies2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-therapeutics-announces-the-establishment-of-its-internal-manufacturing-facility-for-process-development-and-scalable-cgmp-production-of-gene-therapies-for-prevalent-serious-diseases2026-07-29T08:38:56-07:00weekly0.5https://kriyatherapeutics.com/news/kriya-therapeutics-announces-80-million-series-a-financing-to-advance-gene-therapies-for-highly-prevalent-serious-diseases2026-07-29T08:38:56-07:00weekly0.5